Literature DB >> 16205868

[Cutaneous side effects of EGF-receptor inhibition and their management].

R Gutzmer1, T Werfel, A Kapp, J Elsner.   

Abstract

The receptor of the epidermal growth factor (EGF-receptor) plays a role in the pathogenesis of many human carcinomas. Recent strategies in anti-tumor therapy target the EGF-receptor, e.g., by the EGF-receptor blocking monoclonal antibody cetuximab or by small molecules inhibiting the tyrosine kinase activity of the EGF-receptor, such as gefitinib and erlotinib. The EGF-receptor is also expressed in normal human skin; in clinical trials with different EGF-receptor inhibitors, cutaneous side effects were common. We report on cutaneous side effects of EGF-receptor blockade, in particular acneiform lesions, xerosis and paronychia, and discuss their management.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16205868     DOI： 10.1007/s00105-005-1033-3

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


  29 in total

1.  Lung cancer prevention: retinoids and the epidermal growth factor receptor-a phoenix rising?

Authors:  Steven D Averbuch
Journal:  Clin Cancer Res       Date:  2002-01       Impact factor: 12.531

2.  Complications of therapy and a diagnostic dilemma case. Case 2. Cutaneous toxicity induced by cetuximab.

Authors:  Marcello Monti; Luca L Mancini; Benvenuto Ferrari; Daoud Rahal; Armando Santoro
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

3.  Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

Authors:  J Baselga; D Rischin; M Ranson; H Calvert; E Raymond; D G Kieback; S B Kaye; L Gianni; A Harris; T Bjork; S D Averbuch; A Feyereislova; H Swaisland; F Rojo; J Albanell
Journal:  J Clin Oncol       Date:  2002-11-01       Impact factor: 44.544

4.  Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225.

Authors:  K J Busam; P Capodieci; R Motzer; T Kiehn; D Phelan; A C Halpern
Journal:  Br J Dermatol       Date:  2001-06       Impact factor: 9.302

5.  Practical management of patients with non-small-cell lung cancer treated with gefitinib.

Authors:  Neelam T Shah; Mark G Kris; William Pao; Leslie B Tyson; Barbara M Pizzo; Murk-Hein Heinemann; Leah Ben-Porat; Dana L Sachs; Robert T Heelan; Vincent A Miller
Journal:  J Clin Oncol       Date:  2004-11-22       Impact factor: 44.544

Review 6.  Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?

Authors:  Romàn Pérez-Soler
Journal:  Oncology (Williston Park)       Date:  2003-11       Impact factor: 2.990

7.  Effects of acyclic retinoid on growth, cell cycle control, epidermal growth factor receptor signaling, and gene expression in human squamous cell carcinoma cells.

Authors:  Masahito Shimizu; Masumi Suzui; Atsuko Deguchi; Jin T E Lim; I Bernard Weinstein
Journal:  Clin Cancer Res       Date:  2004-02-01       Impact factor: 12.531

8.  Successful treatment of multifocal bronchioloalveolar cell carcinoma with ZD1839 (Iressa) in two patients.

Authors:  Gee-Chen Chang; Tsung-Ying Yang; Nai-San Wang; Chih-Mei Huang; Chi-Der Chiang
Journal:  J Formos Med Assoc       Date:  2003-06       Impact factor: 3.282

9.  Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

Authors:  Denis Soulieres; Neil N Senzer; Everett E Vokes; Manuel Hidalgo; Sanjiv S Agarwala; Lillian L Siu
Journal:  J Clin Oncol       Date:  2004-01-01       Impact factor: 44.544

10.  Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.

Authors:  Eric K Rowinsky; Garry H Schwartz; Jared A Gollob; John A Thompson; Nicholas J Vogelzang; Robert Figlin; Ronald Bukowski; Naomi Haas; Pamela Lockbaum; Yu-Ping Li; Rosalin Arends; Kenneth A Foon; Gisela Schwab; Janice Dutcher
Journal:  J Clin Oncol       Date:  2004-06-21       Impact factor: 44.544
View more
  5 in total

1.  [Cutaneous side effects of medical tumor therapy].

Authors:  A Degen; M Alter; F Schenck; A Kapp; R Gutzmer
Journal:  Hautarzt       Date:  2011-06       Impact factor: 0.751

2.  Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers.

Authors:  Weon Ju Lee; Seong Geun Chi; Dong Jae Park; Jun Young Kim; Ho Youn Kim; Seok-Jong Lee; Do Won Kim; Moon Kyu Kim; Jung Chul Kim; Mi Woo Lee
Journal:  Ann Dermatol       Date:  2011-02-28       Impact factor: 1.444

3.  [Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid].

Authors:  A Wollenberg; N Moosmann; J Kroth; V Heinemann; E Klein
Journal:  Hautarzt       Date:  2007-07       Impact factor: 0.751

Review 4.  Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.

Authors:  Mario E Lacouture; Milan J Anadkat; René-Jean Bensadoun; Jane Bryce; Alexandre Chan; Joel B Epstein; Beth Eaby-Sandy; Barbara A Murphy
Journal:  Support Care Cancer       Date:  2011-06-01       Impact factor: 3.603

5.  Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth.

Authors:  Serena P H Mao; Minji Park; Ramon M Cabrera; John R Christin; George S Karagiannis; Maja H Oktay; Dietmar M W Zaiss; Scott I Abrams; Wenjun Guo; John S Condeelis; Paraic A Kenny; Jeffrey E Segall
Journal:  Breast Cancer Res       Date:  2018-10-26       Impact factor: 6.466
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.